Figure S5: (A) Bayesian-based residual deviance NMA/UME model of primary outcome: incidence of hearing loss, (B) Bayesian-based per-arm residual deviance of primary outcome: incidence of hearing loss, (C) Bayesian-based leverage plot of primary outcome: incidence of hearing loss, (D) Bayesian-based residual deviance NMA/UME model of primary outcome: incidence of hearing loss in subgroup of dosage, (E) Bayesian-based per-arm residual deviance of primary outcome: incidence of hearing loss in subgroup of dosage, (F) Bayesian-based leverage plot of primary outcome: incidence of hearing loss in subgroup of dosage, (G) Bayesian-based residual deviance NMA/UME model of drop-out rate, (H) Bayesian-based per-arm residual deviance of drop-out rate, (I) Bayesian-based leverage plot of drop-out rate
And so Im still there
Sources: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Gastric pentadecapeptide body protection compound BPC 157 and its role in soft tissue healing Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-eNOS pathway Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing The product is intended for scientific research and laboratory analysis
Treatment frequency can vary, but many clinics recommend weekly injections for optimal results
Across the wider UK peptides market, this helps researchers compare suppliers using documented evidence rather than relying on general purity claims
